A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Flumazenil (Primary)
- Indications Hypersomnia; Narcolepsy
- Focus Therapeutic Use
- 12 Dec 2017 Biomarkers information updated
- 16 Mar 2012 Actual end date (1 Jan 2012) added as reported by ClinicalTrials.gov.
- 16 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.